ArticleAJPM focus2025
Association Between Opioid Dosage Tapering and Opioid Overdose Among Long-Term Higher-Dose Opioid Users.
Article in AJPM focus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There has been a steady decline in the national opioid-dispensing rate in recent years. However, emerging evidence that suggests that abrupt discontinuation of opioids for pain may increase overdose risk. The authors examined associations between prescribed opioid tapering and short-term risk of overdose among adults who have received a new long-term high-dose opioid prescription. Methods: This cohort study included adults (aged ≥18 years) without cancer who were newly prescribed a long-term high-dose opioid, that is, daily dose ≥50 morphine milligram equivalents for ≥183 days, between 2013 and 2018 in Kaiser Permanente Southern California. Opioid tapering within the evaluation period (3 months after being prescribed long-term high-dose opioid) was defined as a reduction ≥10% in monthly morphine milligram equivalents for at least 2 consecutive months compared with baseline morphine milligram equivalents. The association of opioid tapering with incident opioid overdose within 12 months was examined separately using multivariable Cox proportional hazard models with inverse probability of treatment weight. Sensitivity analyses were performed to differentiate the association by tapering rates. Results: Among 12,866 eligible individuals, 7,372 (57.3%) initiated tapering within 3 months. Seventy-five patients had a documented opioid overdose event within 12 months during follow-up, resulting in an incidence rate of 0.022 and 0.013 event per 1,000 person-years, respectively, among the nontapered and tapered cohorts. Tapering within the evaluation period was associated with a 0.48 (hazard ratio=0.52; 95% CI=0.33, 0.82) reduction in risk of overdose in the subsequent 12 months. Sensitivity analyses suggested that a tapering rate of 20%-40% reduction monthly was associated with lower risk. Conclusions: Among patients newly prescribed long-term high-dose opioids, initiating tapering within 3 months was shown to be associated with reduced short-term risk of opioid overdose. However, more studies are needed for further confirmation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.